Shamburg News · 8-K filed Nov 16, 2026, 4:11 PM EST
Connect Biopharma Reports Q3 2026 Results and Receives Nasdaq Minimum Bid Price Notice
CNTB · Connect Biopharma Holdings Ltd
- Earnings
- Delisting
- Materiality: high
Connect Biopharma Holdings Limited reported a net loss of $16.2 million, or $0.26 per share, for the three months ended September 30, 2026, on license and collaboration revenues of $0.7 million. Cash, cash equivalents and short-term investments were $19.5 million as of September 30, 2026. On November 12, 2026, the Company received a Nasdaq letter stating that its ordinary shares had closed below the $1.00 minimum bid price for thirty consecutive business days, and it was granted until May 11, 2027 to regain compliance.
Source: SEC EDGAR, Form 8-K, Items 2.02, 3.01, accession 0001835268-26-000045.
Written from the filing by Shamburg Markets. Figures are as reported by the company.